ImmuSAFE™ COVID+ Biochip

Product Specifications

Product Name ImmuSAFE™ COVID+ Biochip Test
Product Name ImmuSAFE™ COVID+ Biochip Test
Platform Sengenics’ KREX™ proprietary surface which preserves protein folding and inhibits binding of non-specific proteins
Content Multiple domains of SARS-CoV-2 Nucleocapsid and Spike proteins including full-length and numerous truncated versions
Number of Arrays 24 arrays per slide (24 samples per slide)
Sample Type Human Serum/Plasma
Assay Type Single-colour fluorescently-labelled antibody assay
Dual-colour fluorescently-labelled antibody assay
System Compatibility Any open-format microarray scanner (Example: Agilent, InnoScan, Genepix or Tecan Scanner)

Biochip Layout


Control Probes:

  • Positive control
    1. Cy3-BSA
    2. Cy5-BSA
    3. IgA (positive control for total immunoglobulins detection)
    4. IgG (positive control for IgG and total immunoglobulins detection)
    5. IgM (positive control for IgM and total immunoglobulins detection)
  • Negative control
    1. IgA (negative control for IgG and IgM detection)
    2. IgG (negative control for IgM detection)
    3. IgM (negative control for IgG detection)
    4. Negative control probe for total immunoglobulins detection


IMMUNOME Protein Array

High-throughput multiplexed autoantibody screening protein array containing 1600+


Contains correctly folded antigens from SARS-CoV-2 and 25 other Corona and Influenza

SARS-CoV-2 Antigens

7 Recombinant SARS-CoV-2 antigens expressed using the patented KREX™ functional proteomics technology


Resources to access our technology


Your technical questions – answered


One technology – endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

© 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361